Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Oct;26(10):1794-1806.
doi: 10.1038/s41590-025-02268-7. Epub 2025 Sep 15.

A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade glioma

Affiliations

A spatial map of MAPK-activated immunosuppressive myeloid populations in pediatric low-grade glioma

Augusto Faria Andrade et al. Nat Immunol. 2025 Oct.

Abstract

Pediatric low-grade gliomas (pLGGs) are mitogen-activated protein kinase (MAPK) pathway-activated brain tumors prevalent in children and are associated with morbidity despite favorable survival. Here using imaging mass cytometry, we spatially characterized at the single-cell level the tumor microenvironment (TME) of 120 pLGG cases, considering age, molecular drivers, brain location and tumor subtype. Our analysis identified myeloid cells-including resident microglia and bone marrow-derived macrophages-as the predominant immune population in the TME, particularly in optic pathway tumors. Additionally, we discovered an immune signature predictive of progression-free survival. Spatial analysis identified specific cellular interactions, notably myeloid-myeloid contacts and macrophage-enriched regions harboring MAPK-activated, TIM-3+ myeloid cells, suggesting an immunosuppressive TME. Our study provides a comprehensive resource on the immune landscape of these pLGGs and underscores the immunosuppressive role of diverse myeloid infiltrates. These findings also indicate that combining TIM-3 blockade with MAPK inhibition might be a promising therapeutic strategy to target both the TME and oncogenic MAPK activation in pLGG tumors.

PubMed Disclaimer

Conflict of interest statement

Competing interests: O.W. and T.M. declare research grant support from Biomed Valley Discoveries and Day One Biopharmaceuticals. The other authors declare no competing interests.

References

    1. Ostrom, Q. T. et al. CBTRUS statistical report: primary brain and other central nervous system tumors diagnosed in the United States in 2016–2020. Neuro. Oncol. 25, iv1–iv99 (2023). - PubMed - PMC
    1. Jones, D. T. et al. Tandem duplication producing a novel oncogenic BRAF fusion gene defines the majority of pilocytic astrocytomas. Cancer Res. 68, 8673–8677 (2008). - PubMed - PMC
    1. Ryall, S., Tabori, U. & Hawkins, C. Pediatric low-grade glioma in the era of molecular diagnostics. Acta Neuropathol. Commun. 8, 30 (2020). - PubMed - PMC
    1. Hardin, E. C. et al. LOGGIC Core BioClinical Data Bank: added clinical value of RNA-seq in an international molecular diagnostic registry for pediatric low-grade glioma patients. Neuro. Oncol. 25, 2087–2097 (2023). - PubMed - PMC
    1. Gnekow, A. K. et al. A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme for childhood (≤16 years) low grade glioma - a final report. Eur. J. Cancer 81, 206–225 (2017). - PubMed - PMC

Substances

LinkOut - more resources